Review Article
Mechanisms of Cellular Effects Directly Induced by Magnetic Nanoparticles under Magnetic Fields
Table 1
In vitro and in vivo studies of different MNPs that have been treated with a variety of cell types under an AMF.
| Kind of MNPs | Size of MNPs | Ration | Cell | Incubation time | Alternating Magnetic field | Exposure time | (°C) | Study type | Cell effects | Ref | intensity | frequency |
| Fe2O3 | 30 nm | 7.5 μg Fe | A549 | 24 h | 208 A/m | 1 MHz | 20 min | 5 | In vitro | Eradicating target cancer cells | [6] |
| Fe3O4 | 12 nm | 2.5 mg Fe | A549 | 1.5 h | 6 kA/m | 386 kHz | 30 min | 13 | In vitro | Inducing the acute necrosis o and a slower, ROS-mediated cell death | [30] |
| Fe/Fe3O4 | 10 nm | 360 μg Fe | B16-F10 | — | 5 kA/m | 366 kHz | 10 min | 11 | In vivo | A decrease in tumor size | [31] |
| Fe3O4 | 20–30 nm | 363 μg Fe | Hela | 24 h | 20 kA/m | 210 kHz | 60 min | 9 | In vitro | Causing about 70% decrease of cell viability | [32] |
| Fe3O4 | 10 nm | ~2.14–7.23 mg Fe | BT474 | — | — | 118 kHz | 30 min | 9 | In vivo | Tumor regression was observed | [33] |
| Fe/MgO | 75 nm | 6.72 mg Fe | MDA cell | 2 h | 20 kA/m | 765 kHz | 10 min | 9 | In vitro | Increasing monotonically within the experimental time interval | [34] |
| Fe3O4 | 72 nm | 6.53 mg Fe | Caco-2 | Immediately | 20 kA/m | 238 kHz | 120 min | 8 | In vitro | A significant decrease in cell viability | [35] |
| Fe3O4 | 20 nm | 725.6 μg Fe | MCF7 | 2 h | 23.3 kA/m | 265 kHz | 10 min | 5 | In vitro | Cell killing was further enhanced | [36] |
| Fe3O4 | 20 nm | 62.5 mg/ml MNPs (half of tumor volume) | Walker-265 | — | 4.4 kA/m | 180 kHz | 30 min | 15 | In vivo | Tumor growth was inhibited and the survival of the tumor-bearing rats was promoted | [37] |
| As2O3/Fe3O4 | 50 nm | 1 mg/ml MNPs (half of tumor volume) | Hela | — | — | 230 kHz | 30 min | 8 | In vivo | A significant inhibitory effect on the mass and volume of xenograft cervical tumors | [38] |
| CoFe2O4/MnFe2O4 | 15 nm | 75 μg MNPs | U87 | — | 37.3 kA/m | 500 kHz | 10 min | 9 | In vivo | The therapeutic efficacy is superior to that of a common anticancer drug | [39] |
|
|